Phase II trial of gemcitabine and docetaxel with bevacizumab in soft tissue sarcoma

Sarcoma

Volumn 2015, Issue , 2015, Pages

  Dickson, Mark A ^a   D'Adamo, David R ^b   Keohan, Mary L ^a   D'Angelo, Sandra P ^a   Carvajal, Richard D ^c   Gounder, Mrinal M ^a   Maki, Robert G ^d   Qin, Li Xuan ^a   Lefkowitz, Robert A ^a   McKennon, Olivia R ^a   Hirst, Catherine M ^a   Schwartz, Gary K ^c   Tap, William D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b EISAI INC   (United States)

^c Department of Medicine Columbia University ^*  (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; DACARBAZINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; PEGFILGRASTIM; PLACEBO; SORAFENIB;

ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANGIOSARCOMA; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CELLULITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM PERFORATION; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; EDEMA; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; LEIOMYOSARCOMA; LIPOSARCOMA; LYMPHOCYTOPENIA; MALE; MUCOSA INFLAMMATION; NECK PAIN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SARCOMA; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; THROMBOSIS;

EID: 84930613983     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2015/532478     Document Type: Article

References (12)

1. M. L. Hensley, R. Maki, E. Venkatraman et al., "Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial", Journal of Clinical Oncology, vol. 20, no. 12, pp. 2824-2831, 2002.
2. J.-O. Bay, I. Ray-Coquard, J. Fayette et al., "Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis", International Journal of Cancer, vol. 119, no. 3, pp. 706-711, 2006.
3. R. G. Maki, J. K. Wathen, S. R. Patel et al., "Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]", Journal of ClinicalOncology, vol. 25, pp. 2755-2763, 2007.
4. M. Agulnik, J. L. Yarber, S. H. Okuno et al., "An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas", Annals of Oncology, vol. 24, no. 1, pp. 257-263, 2013.
5. D. R. D'Adamo, S. E. Anderson, K. Albritton et al., "Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas", Journal of Clinical Oncology, vol. 23, no. 28, pp. 7135-7142, 2005.
6. E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", European Journal of Cancer, vol. 45, no. 2, pp. 228-247, 2009.
7. M. L. Hensley, J. A. Blessing, K. DeGeest, O. Abulafia, P. G. Rose, and H. D. Homesley, "Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study", Gynecologic Oncology, vol. 109, no. 3, pp. 323-328, 2008.
8. M. L. Hensley, J. A. Blessing, R. Mannel, and P. G. Rose, "Fixeddose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial", Gynecologic Oncology, vol. 109, no. 3, pp. 329-334, 2008.
9. M. Van Glabbeke, J. Verweij, I. Judson, and O. S. Nielsen, "Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas", European Journal of Cancer, vol. 38, no. 4, pp. 543-549, 2002.
10. P. Pautier, A. Floquet, N. Penel et al., "Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a fédération nationale des centres de lutte contre le cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)", Oncologist, vol. 17, no. 9, pp. 1213-1220, 2012.
11. C. F. Verschraegen, H. Arias-pulido, S.-J. Lee et al., "Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen", Annals of Oncology, vol. 23, no. 3, pp. 785-790, 2012.
12. N. Penel, J. Y. Blay, O. Mir et al., "ANGIOTAX-PLUS trial: a randomized phase II trial assessing the activity of weekly paclitaxel plus or minus bevacizumab in advanced angiosarcoma", Journal of Clinical Oncology, vol. 32, abstract 10501, 2014.